Original Title: Palivizumab para prevenir infecciones respiratorias bajas por virus sincicial respiratorio

Authors' recommendations: High quality evidence shows that palivizumab is effective in reducing the number of hospitalizations and admissions to Intensive Care in premature patients and patients with hemodynamically significant congenital heart diseases, although it has not impact on mortality. There is consensus in clinical practice guidelines on recommending the use of palivizumab during the respiratory syncytial virus season in patients at high risk of acquiring severe infections due to this virus. There are differences among the guidelines in terms of the criteria defining the population with indication for palivizumab. Most health funders, both public and private, from high-income countries and Latin America funders recommend the use of palivizumab, except for Australia, where it is not recommended since the benefit-cost ratio was not favorable to cover this drug. There is a significant heterogeneity among the economic evaluations in determining the cost-effectiveness of palivizumab, with some studies showing that it is a cost-saving option, and estimates that consider an incremental cost-effectiveness ratio higher than one million dollars per quality adjusted life year.

Project Status: Completed

Year Published: 2019

URL for published report: https://www.iecs.org.ar/home-ets/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Argentina

Organisation Name: Institute for Clinical Effectiveness and Health Policy

Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA

Contact Name: info@iecs.org.ar

Contact Email: info@iecs.org.ar

Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)